Comparison of initial efficacy and long-term follow-up of heparin-coated Jostent with conventional NIR stent

Japanese Heart Journal

Volumn 44, Issue 6, 2003, Pages 889-898

  Semiz, Ender ^a   Ermiş, Cengiz ^b   Yalçinkaya, Selim ^b   Sancaktar, Oktay ^b   Deǧer, Necmi ^b  

^a PAMUKKALE UNIVERSITY   (Turkey)

^b AKDENIZ UNIVERSITY   (Turkey)

Author keywords

Coating; Coronary disease; Coronary stents; Heparin; Restenosis

Indexed keywords

HEPARIN; BIOMATERIAL;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CARDIOVASCULAR SURGERY; COMPARATIVE STUDY; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; CORONARY STENT; EMERGENCY TREATMENT; FEMALE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MATERIAL COATING; MORTALITY; OUTCOMES RESEARCH; PRIORITY JOURNAL; RESTENOSIS; THROMBOSIS; CORONARY ARTERY THROMBOSIS; FOLLOW UP; HEART MUSCLE REVASCULARIZATION; MIDDLE AGED; RETROSPECTIVE STUDY; STENT;

AGED; COATED MATERIALS, BIOCOMPATIBLE; CORONARY DISEASE; CORONARY RESTENOSIS; CORONARY THROMBOSIS; FEMALE; FOLLOW-UP STUDIES; HEPARIN; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL REVASCULARIZATION; RETROSPECTIVE STUDIES; STENTS;

EID: 1242308949     PISSN: 00214868     EISSN: 1348673X     Source Type: Journal    
DOI: 10.1536/jhj.44.889     Document Type: Article

References (44)

1. Rogers C, Edelman ER. Endovascular stent design dictates experimental restenosis and thrombosis. Circulation 1995; 91: 2995-3001.
2. Härdhammar PA, van Beusekom HMM, Emanuelsson HU, et al. Reduction in thrombotic events with heparincoated Palmaz-Schatz stents in normal porcine coronary arteries. Circulation 1996; 93: 423-30.
3. De Scheerder I, Wang K, Wilczek K, et al. Experimental study of thrombogenicity and foreign body reaction induced by heparin-coated coronary stents. Circulation 1997; 95: 1549-53.
4. Serruys PW, Emanuelsson H, van der Giessen W, et al. on behalf of the BENESTENT II Study Group. Heparin-coated Palmaz-Schatz stents in human coronary arteries: early outcome of the BENESTENT II Pilot Study. Circulation 1996; 93: 412-22.
5. Serruys PW, van Hout B, Bonnier H, et al. Randomised comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (Benestent II). Lancet 1998; 352: 673-81.
6. Roubin GS, Cannon AD, Agrawal S, et al. Intracoronary stenting for acute and threatened closure complicating PTCA. Circulation 1992; 85: 916-27.
7. Fischman DL, Leon MB, Baim DS, et al. A randomized comparison of coronary stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med 1994; 331: 496-501.
8. Serruys PW, de Jaegere P, Kiemeneij F, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med 1994; 331: 489-95.
9. Rodriguez AE, Santaera O, Larribau M, et al. Coronary stenting decreases restenosis in lesions with early loss of luminal diameter 24 hours after successful PTCA. Circulation 1995; 91: 1397-402.
10. Leon MB, Baim DS, Popma JJ, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary artery stenting: Stent Anti-coagulation Restenosis Study Investigators. N Engl J Med 1998; 339: 1665-71.
11. Holmes DR, Camrud AR, Jorgenson MA, Edwards WD, Schwartz RS. Polymeric stenting in the porcine coronary artery model: differential outcome of exogenous fibrin sleeves versus polyurethane-coated stents. J Am Coll Cardiol 1994; 24: 525-31.
12. Kuiper KK, Robinson KA, Chronos NA, et al. Phosphorylcholine-coated metallic stents in rabbit iliac and porcine coronary arteries. Scand Cardiovasc J 1998; 32: 261-8.
13. Whelan DM, van der Giessen WJ, Krabbendam SC, et al. Biocompatibility of phosphorylcholine coated stents in normal porcine coronary arteries. Heart 2000; 83: 338-45.
14. De Scheerder IK, Wilczek K, Verbeken E, et al. Biocompatibility of biodegradable and nonbiodegradable polymer-coated stents implanted in porcine peripheral arteries. Cardiovasc Intervent Radiol 1995; 18: 227-32.
15. Rechavia E, Litvack F, Fishbein MC, Nakamura M, Eigler N. Biocompatibility of polyurethane coated stents: tissue and vascular aspects. Cathet Cardiovasc Diagn 1998; 45: 202-7.
16. Malik N, Gunn J, Shepherd L, Crossman DC, Cumberland DC, Holt CM. Phosphorylcholine-coated stents in porcine coronary arteries: in vivo assessment of biocompatibility. J Invasive Cardiol 2001; 13: 193-201.
17. Staab ME, Holmes DR Jr, Schwartz RS. Polymers. In: Sigwart U, ed. Endoluminal Stenting. London, UK: WB Saunders; 1996; 34-44.
18. Cox DA, Anderson PG, Roubin GS, Chou CY, Agrawal SK, Cavender JB. Effects of local delivery of heparin and methotrexate on neointimal proliferation in stented porcine coronary arteries. Coron Artery Dis 1992; 3: 237-48.
19. Slepian MJ. Polymeric endoluminal gel paving: therapeutic hydrogel barriers and sustained drug delivery depots for local arterial wall biomanipulation. Semin Interv Cardiol 1996; 1: 103-16.
20. Schwartz RS, Murphy JG, Edwards WD, Holmes DR. Bioabsorbable, drug eluting, intracoronary stents: design and future applications. In: Sigwart U, Frank GI eds. Coronary Stents. Berlin, Germany: Springer-Verlag; 1992: 135-54.
21. New G, Moses JW, Roubin GS, et al. Estrogen-eluting, phosphorylcholine-coated stent implantation is associated with reduced neointimal formation but no delay in vascular repair in a porcine coronary model. Catheter Cardiovasc Interv 2002; 57: 266-71.
22. Galli M, Sommariva L, Prati F, et al. Acute and mid-term results of phosphorylcholine-coated stents in primary coronary stenting for acute myocardial infarction. Catheter Cardiovasc Interv 2001; 53: 182-7.
23. Byer A, Peters S, Settepani F, Pagliaro M, Galletti G. Fibrin sealant coated stents compared with non-coated stents in a porcine carotid artery model. Preliminary study report. J Cardiovasc Surg (Torino) 2001; 42: 543-9.
24. Baker JE, Horn JB, Nikolaychik V, Kipshidze NN. Fibrin stent coatings. In: Sigwart U ed. Endoluminal Stenting. London, UK: WB Saunders; 1996: 84-9.
25. Grenadier E, Roguin A, Hertz I, et al. Stenting very small coronary narrowings (< 2 mm) using the biocompatible phosphorylcholine-coated coronary stent. Catheter Cardiovasc Interv 2002; 55: 303-8.
26. Aggarwal RK, Ireland DC, Azrin MA, Ezekowitz MD, de Bono DP, Gershlick AH. Antithrombotic potential of polymer-coated stents eluting platelet glycoprotein IIb/IIIa receptor antibody. Circulation 1996; 94: 3311-7.
27. Bar FW, van der Veen FH, Benzina A, Habets J, Koole LH. New biocompatible polymer surface coating for stents results in a low neointimal response. J Biomed Mater Res 2000; 52: 193-8.
28. Larm O, Larsson R, Olsson P. A new non-thrombogenic surface prepared by selective covalent binding of heparin via a reducing terminal residue. Biomater Med Devices Artif Organs 1983; 11: 161-74.
29. Vrolix MC, Legrand VM, Reiber JH, et al. Heparin-coated Wiktor stents in human coronary arteries (MENTOR trial). MENTOR Trial Investigators. Am J Cardiol 2000; 86: 385-9.
30. Topol EJ, Serruys PW. Frontiers in interventional cardiology. Circulation 1998; 98: 1802-20.
31. Matsumoto Y, Shimokawa H, Morishige K, Eto Y, Takeshita A. Reduction in neointimal formation with a stent coated with multiple layers of releasable heparin in porcine coronary arteries. J Cardiovasc Pharmacol 2002; 39: 513-22.
32. Serruys PW, van Hout B, Bonnier H, et al. Randomised comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (Benestent II). Lancet 1998; 352: 673-81.
33. Kedev S, Guagliumi G, Valsechi O, Tespili M. Heparin-coated versus uncoated Palmaz-Schatz stent in native coronary circulation. A randomized study with blind angioscopic assessment. Int J Artif Organs 2002; 25: 461-9.
34. Baim DS, Cutlip DE, O'Shaughnessy CD, et al.; NIRVANA Investigators (NIR Vascular Advanced North American Trial). Final results of a randomized trial comparing the NIR stent to the Palmaz-Schatz stent for narrowings in native coronary arteries. Am J Cardiol 2001; 87: 152-6.
35. Eeckhout E, Wijns W, Meier B, Goy JJ, on behalf of the members of the Working Group on Coronary Circulation of the European Society of Cardiology. Indications for intracoronary stent placement: the European view. Eur Heart J 1999; 20: 1014-9.
36. de Jaegere PPF, Eefting FD, Popma JJ, Serruys PW. Clinical trials on intracoronary stenting. Semin Intervent Cardiol 1996; 1: 233-45.
37. Serruys P, Grines C, Stone G, et al. Stent implantation in acute myocardial infarction using a heparin-coated stent: a pilot study as a preamble to a randomized trial comparing balloon angioplasty and stenting. Int J Cardiovasc Intervent 1998; 1: 19-27.
38. Wohrle J, Al-Khayer E, Grotzinger U, et al. Comparison of the heparin coated vs the uncoated Jostent - no influence on restenosis or clinical outcome. Eur Heart J 2001; 22: 1808-16.
39. Forrester JS, Fishbein M, Helfant R, Fagin J. A paradigm for restenosis based on cell biology: Clues for the development of new preventive therapies. J Am Coll Cardiol 1991; 17: 758-69.
40. Kastrati A, Dirschinger J, Boekstegers P, et al. Influence of stent design on 1-year outcome after coronary stent placement: a randomized comparison of five stent types in 1,147 unselected patients. Catheter Cardiovasc Interv 2000; 50: 290-7.
41. Mehilli J, Kastrati A, Dirschinger J, et al. A randomized trial comparing the hand-mounted Jostent with the premounted Multi-Link Duet stent in patients with coronary artery disease. Catheter Cardiovasc Interv 2001; 54: 414-9.
42. Kastrati A, Mehilli J, Dirschinger J, et al. Intracoronary stenting and angiographic results. Strut Thickness Effect on Restenosis Outcome (ISAR-STEREO) Trial. Circulation 2001; 103: 2816-21.
43. Nelson SR, deSouza NM, Allison DJ. Endovascular stents and stent-grafts: is heparin coating desirable? Cardiovasc Intervent Radiol 2000; 23: 252-5.
44. van Der Giessen WJ, van Beusekom HM, Larsson R, Serruys P. Heparin-coated coronary stents. Curr Interv Cardiol Rep 1999; 1: 234-40.